Cryopyrin Associated Periodic Syndrome
7
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
Circadian Rhythm Deregulation in Patients With CAPS
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome
Adult Outcomes of Children With CAPS
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)
Are Mast Cells Involved in Autoinflammatory Diseases
Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada